A Randomized, Prospective Field Trial of a Conjugate Vaccine in the Protection of Infants and Young Children against InvasiveHaemophilus influenzaeType b Disease
- 15 November 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (20), 1381-1387
- https://doi.org/10.1056/nejm199011153232004
Abstract
Haemophilus influenzae type b is the leading cause of invasive bacterial disease in young children. The capsular polysaccharide vaccine does not protect children at greatest risk (those under the age of 18 months), but a polysaccharide—protein conjugate vaccine has proved to be more immunogenic in this age group. We enrolled 114,000 infants in Finland in an open, prospective, randomized trial of a H. influenzae type b capsular polysaccharide—diphtheria toxoid conjugate vaccine (polyribosylribitol phosphate—diphtheria toxoid [PRP-D]). Children born on odd-numbered days were vaccinated at the ages of 3, 4, 6, and 14 to 18 months; those born on even-numbered days formed the control group and received the same vaccine at the age of 24 months. After three doses of the vaccine there were 4 cases of verified bacteremic H. influenzae type b disease in the group receiving early vaccination, as compared with 64 cases in the control group, between the ages of approximately 7 and 24 months. The protective efficacy of the vaccine was thus 94 percent (95 percent confidence interval, 83 to 98). No serious adverse effects were reported. The immune response to the conjugate vaccine was characteristic of a T-cell—dependent response when studied in a cohort of 120 infants. The primary immunization series resulted in a geometric mean concentration of anticapsular antibody of 0.53 μg per milliliter at the age of seven months, and the fourth dose evoked an anamnestic response, with a mean antibody concentration of 45.22 μg per milliliter. A new conjugate vaccine consisting of the capsular polysaccharide of H. influenzae type b covalently linked to a protein carrier (PRP-D), administered to infants beginning at the age of 3 months, is highly effective in protecting young Finnish children (7 to 24 months old) against invasive H. influenzae type b infections. (N Engl J Med 1990; 323:1381–7.)This publication has 25 references indexed in Scilit:
- Risk factors of invasive Haemophilus influenzae type b disease among children in FinlandThe Journal of Pediatrics, 1989
- Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b diseaseThe Journal of Pediatrics, 1988
- Haemophilus influenzae Type b Anticapsular Antibody Responses to PRP-Pertussis and PRP-D Vaccines in Alaska Native InfantsThe Journal of Infectious Diseases, 1988
- Efficacy ofHaemophilus IinfluenzaeType b Polysaccharide–Diphtheria Toxoid Conjugate Vaccine in InfancyNew England Journal of Medicine, 1987
- IMMUNOGENICITY IN INFANTS OF HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE IN A CONJUGATE VACCINE WITH NEISSERIA MENINGITIDIS OUTER-MEMBRANE PROTEINThe Lancet, 1986
- ANTIBODY LEVELS ACHIEVED IN INFANTS BY COURSE OF HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE/DIPHTHERIA TOXOID CONJUGATE VACCINEThe Lancet, 1985
- Prevention ofHemophilus influenzaeType B Bacteremic Infections with the Capsular Polysaccharide VaccineNew England Journal of Medicine, 1984
- HAEMOPHILUS INFLUENZAE DISEASE IN ALASKAN ESKIMOS: CHARACTERISTICS OF A POPULATION WITH AN UNUSUAL INCIDENCE OF INVASIVE DISEASEThe Lancet, 1981
- Serum Antibodies to Capsular Polysaccharide Vaccine of Group A Neisseria meningitidis Followed for Three Years in Infants and ChildrenThe Journal of Infectious Diseases, 1980
- Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.The Journal of Experimental Medicine, 1980